Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbidol for Allergic Rhinitis
NCT06462417Recruiting
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of umifenovir in allergic rhinitis (AR). Primary endpoints: Protein level of molecular biomarkers in nasal epithelial cells at 14 days, mRNA level of inflammation molecular biomarkers in nasal epithelial cells at 14 days and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
umifenovir
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06462417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462417.